Dasatinib—A Generation Ahead
Keyword(s):
AbstractDasatinib is a highly potent second-generation (2G) tyrosine kinase inhibitor (TKI) used in the management of Philadelphia (Ph) chromosome-positive leukemias, chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). In CML, dasatinib produces higher rates of early and deeper molecular responses compared with imatinib. The drug has its share of toxicities, namely, cytopenias, cardiovascular, and pleural effusion. This review describes the pharmacological aspects of dasatinib, clinically relevant toxicities, and their management.
2014 ◽
Vol 56
(6)
◽
pp. 1787-1792
◽
2011 ◽
Vol 33
(6)
◽
pp. 455-460
2013 ◽
Vol 13
(7)
◽
pp. 755-767
◽
2019 ◽
Vol 4
(1-2)
◽
pp. 41-45
◽
2017 ◽
Vol 35
(5)
◽
pp. 567-567
◽